Other
Depreciation, Amortization and Accretion, Net
Alnylam Pharmaceuticals Depreciation, Amortization and Accretion, Net increased by 0.3% to $13.55M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 5.9%, from $14.41M to $13.55M. Over 4 years (FY 2021 to FY 2025), Depreciation, Amortization and Accretion, Net shows an upward trend with a 4.0% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementIncome Statement
SectionOther
CategoryEfficiency
SignalLower is better
VolatilityStable
First reportedQ1 2016
Last reportedQ1 2026Apr 30, 2026
How to read this metric
Higher values indicate a larger capital asset base or significant recent investments in intangible assets.
Detailed definition
The total non-cash expense recognized for the allocation of the cost of tangible and intangible assets over their useful...
Peer comparison
Standard operating expense metric across all capital-intensive industries.
Metric ID:
other_depreciation_amortization_and_accretion_netHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $11.81M | $11.79M | $11.38M | $9.46M | $10.10M | $10.60M | $14.31M | $14.07M | $13.18M | $13.33M | $13.48M | $13.52M | $15.00M | $13.98M | $14.17M | $14.41M | $13.94M | $13.80M | $13.51M | $13.55M |
| QoQ Change | — | -0.2% | -3.5% | -16.8% | +6.7% | +5.0% | +35.0% | -1.7% | -6.3% | +1.1% | +1.2% | +0.3% | +11.0% | -6.8% | +1.3% | +1.7% | -3.2% | -1.0% | -2.2% | +0.3% |
| YoY Change | — | — | — | — | -14.5% | -10.1% | +25.8% | +48.7% | +30.5% | +25.7% | -5.8% | -3.9% | +13.8% | +4.9% | +5.1% | +6.6% | -7.1% | -1.3% | -4.7% | -5.9% |
Range$9.46M – $15.00M
CAGR+2.9%
Avg YoY Growth+6.8%
Median YoY Growth+1.8%
Depreciation, Amortization and Accretion, Net at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's depreciation, amortization and accretion, net?
- Alnylam Pharmaceuticals (ALNY) reported depreciation, amortization and accretion, net of $13.55M in Q1 2026.
- How has Alnylam Pharmaceuticals's depreciation, amortization and accretion, net changed year-over-year?
- Alnylam Pharmaceuticals's depreciation, amortization and accretion, net decreased by 5.9% year-over-year, from $14.41M to $13.55M.
- What is the long-term trend for Alnylam Pharmaceuticals's depreciation, amortization and accretion, net?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's depreciation, amortization and accretion, net has grown at a 4.0% compound annual growth rate (CAGR), from $47.57M to $55.66M.
- What does depreciation, amortization and accretion, net mean?
- Total non-cash expenses for the wear and tear or expiration of assets.